Total pharma venture financing deals in Q4 2018 worth $4.71bn were announced globally, according to GlobalData’s deals database.
Go deeper with GlobalData
- Embed this chart
Embed this chart into your website
Copy and paste the code below into your website to display the chart.
The value marked an increase of 4.1% over the previous quarter and a drop of 7.5% when compared with the last four-quarter average, which stood at $5.13bn.
Comparing deals value in different regions of the globe, North America held the top position, with total announced deals in the period worth $3.52bn. At the country level, the United States topped the list in terms of deal value at $3.49bn.
In terms of volumes, North America emerged as the top region for pharma venture financing deals globally, followed by Europe and then Asia-Pacific.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe top country in terms of venture financing deals activity in Q4 2018 was the United States with 159 deals, followed by China with 21 and the United Kingdom with 11.
In 2018, as of the end of Q4, pharma venture financing deals worth $21.44bn were announced globally, marking an increase of 66.1% year on year.
Pharma venture financing deals in Q4 2018: Top deals
The top five pharma venture financing deals accounted for 25.3% of the overall value during Q4 2018.
The combined value of the top five pharma venture financing deals stood at $1.19bn, against the overall value of $4.71bn recorded for the quarter.
The top announced pharma venture financing deal tracked by GlobalData in Q4 2018 was Data Collective Venture Capital, DFJ Venture, The Goldman Sachs Group, Hanwha Asset Management, Innovation Endeavors, SoftBank Vision Fund, True Ventures and Two Sigma Ventures’ $400m venture financing of Zymergen.
In second place was Alexandria Venture Investments, BVF Partners, Casdin Capital, D. E. Shaw Research, EcoR1 Capital, Foresite Capital Management, GV Management Co, Perceptive Advisors, SoftBank Vision Fund and Tavistock Group’s venture financing of Relay Therapeutics for $400m and in third place was China Industrial Asset Management, China Pacific Capital, Haier Capital and Legend Capital’s $136m venture financing of Shanghai Cell Therapy Group.
Rakuten and SBI Holdings’ $134m venture financing of Rakuten Aspyrian and Deerfield Management, Frazier Healthcare Partners, New Enterprise Associates, Novo Holdings, Pappas Capital, RiverVest Venture Partners and Rock Springs Capital Management’s venture financing of Mirum Pharmaceuticals for $120m held fourth and fifth positions, respectively.
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.
